Oncology Institute Future Growth
Future criteria checks 1/6
Oncology Institute is forecast to grow earnings and revenue by 30.7% and 19.5% per annum respectively.
Key information
30.7%
Earnings growth rate
n/a
EPS growth rate
| Healthcare earnings growth | 17.3% |
| Revenue growth rate | 19.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Apr 2024 |
Recent future growth updates
Recent updates
Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%
Mar 21
Is Oncology Institute (NASDAQ:TOI) A Risky Investment?
Mar 05The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company
Nov 10The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit
Aug 09Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings
May 18Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth
Mar 16The Oncology Institute: Capitalizing On Clinical Research Contracts
Dec 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 483 | -36 | -20 | -14 | 1 |
| 12/31/2024 | 413 | -50 | -34 | -29 | 1 |
| 12/31/2023 | 324 | -68 | -41 | -36 | N/A |
| 9/30/2023 | 310 | -61 | -52 | -46 | N/A |
| 6/30/2023 | 293 | -50 | -64 | -59 | N/A |
| 3/31/2023 | 274 | -40 | -67 | -60 | N/A |
| 12/31/2022 | 252 | 0 | -67 | -62 | N/A |
| 9/30/2022 | 233 | -1 | -75 | -71 | N/A |
| 6/30/2022 | 221 | -2 | -58 | -53 | N/A |
| 3/31/2022 | 210 | 6 | -54 | -50 | N/A |
| 12/31/2021 | 203 | -11 | -36 | -33 | N/A |
| 9/30/2021 | 200 | -6 | -13 | -10 | N/A |
| 6/30/2021 | 195 | -3 | -12 | -10 | N/A |
| 3/31/2021 | 192 | -5 | -11 | -9 | N/A |
| 12/31/2020 | 188 | -14 | -1 | 1 | N/A |
| 12/31/2019 | 155 | -4 | 2 | 4 | N/A |
| 12/31/2018 | 113 | -2 | 5 | 6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TOI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TOI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TOI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TOI's revenue (19.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: TOI's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TOI's Return on Equity is forecast to be high in 3 years time